Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19070259 | METHODS AND SYSTEMS FOR DETECTING GENETIC VARIANTS | March 2025 | April 2025 | Allow | 2 | 1 | 0 | No | No |
| 18958854 | SEQUENCING A TARGET SEQUENCE IN A CELL | November 2024 | June 2025 | Allow | 6 | 1 | 0 | No | No |
| 18930072 | METHODS FOR MONITORING RESIDUAL DISEASE | October 2024 | February 2025 | Allow | 13 | 1 | 0 | Yes | No |
| 18900948 | METHOD, KIT AND SYSTEM FOR END LABELING OF NUCLEIC ACIDS | September 2024 | June 2025 | Allow | 8 | 1 | 1 | Yes | No |
| 18813477 | METHODS AND SYSTEMS FOR DETECTING GENETIC VARIANTS | August 2024 | February 2025 | Allow | 6 | 1 | 0 | No | No |
| 18812385 | METHODS AND SYSTEMS FOR DETECTING GENETIC VARIANTS | August 2024 | February 2025 | Allow | 5 | 1 | 0 | No | No |
| 18776193 | DEVICES AND METHODS FOR ANALYZING BIOLOGICAL SAMPLES | July 2024 | January 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 18770298 | METHODS AND SYSTEMS FOR ANALYZING NUCLEIC ACID MOLECULES | July 2024 | March 2025 | Allow | 8 | 1 | 0 | No | No |
| 18770271 | METHODS AND SYSTEMS FOR ANALYZING NUCLEIC ACID MOLECULES | July 2024 | December 2024 | Allow | 5 | 1 | 0 | No | No |
| 18737828 | PROBE-BASED ANALYSIS OF NUCLEIC ACIDS AND PROTEINS | June 2024 | March 2025 | Abandon | 9 | 1 | 0 | No | No |
| 18737230 | SYSTEMS AND METHODS FOR SEQUENCING ERROR CORRECTION VIA DOUBLE STRAND PRESERVATION | June 2024 | September 2024 | Allow | 4 | 1 | 0 | No | No |
| 18677090 | SYSTEMS AND METHODS TO DETECT RARE MUTATIONS AND COPY NUMBER VARIATION | May 2024 | February 2025 | Allow | 9 | 1 | 0 | No | No |
| 18672154 | Adenosine triphosphatase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 (ATP2A2) gene-based molecular marker for identifying chicken feed efficiency trait, and identification method and use thereof | May 2024 | March 2025 | Allow | 10 | 1 | 0 | No | No |
| 18655106 | METHODS FOR PROCESSING NUCLEIC ACID SAMPLES | May 2024 | June 2025 | Abandon | 13 | 2 | 0 | No | No |
| 18625882 | METHODS AND SYSTEMS FOR ANALYZING NUCLEIC ACID MOLECULES | April 2024 | April 2025 | Allow | 12 | 2 | 0 | No | No |
| 18593787 | METHODS FOR ANALYZING BIOLOGICAL SAMPLES IN A FLUIDIC DEVICE COMPRISING GENERATING A POLYMER MATRIX FROM PRECURSORS AT SPECIFIC LOCATIONS COMPRISING BIOLOGICAL COMPONENTS | March 2024 | July 2024 | Allow | 4 | 1 | 0 | Yes | No |
| 18426665 | SYSTEMS AND METHODS TO DETECT RARE MUTATIONS AND COPY NUMBER VARIATION | January 2024 | January 2025 | Allow | 11 | 1 | 0 | No | No |
| 18392743 | METHODS AND SYSTEMS FOR NUCLEIC ACID ANALYSIS | December 2023 | April 2025 | Abandon | 16 | 2 | 0 | No | No |
| 18569594 | SPATIAL ANALYSIS OF A PLANAR BIOLOGICAL SAMPLE | December 2023 | December 2024 | Allow | 12 | 1 | 0 | No | No |
| 18460755 | SINGLE CELL SEQUENCING | September 2023 | February 2025 | Allow | 17 | 1 | 0 | No | No |
| 18350601 | IMMUNE PROFILING USING SMALL VOLUME BLOOD SAMPLES | July 2023 | July 2025 | Allow | 24 | 1 | 0 | No | No |
| 18345676 | METHOD OF DETECTING AND QUANTIFYING GENOMIC AND GENE EXPRESSION ALTERATIONS USING RNA | June 2023 | June 2025 | Allow | 24 | 1 | 0 | No | No |
| 18343858 | MATERIALS AND METHODS FOR LOCALIZED DETECTION OF NUCLEIC ACIDS IN A TISSUE SAMPLE | June 2023 | February 2025 | Allow | 19 | 1 | 0 | No | No |
| 18341446 | METHODS, COMPOSITIONS, AND KITS FOR PREPARING NUCLEIC ACID LIBRARIES | June 2023 | January 2025 | Allow | 19 | 1 | 0 | No | No |
| 18205795 | DIAGNOSIS OF PROSTATE CANCER | June 2023 | May 2025 | Allow | 24 | 2 | 0 | No | No |
| 18320122 | METHODS AND ARRAYS FOR PRODUCING AND SEQUENCING MONOCLONAL CLUSTERS OF NUCLEIC ACID | May 2023 | January 2025 | Allow | 20 | 1 | 0 | No | No |
| 18313277 | METHODS OF LABELLING NUCLEIC ACIDS USING VARIABLE LENGTH OLIGONUCLEOTIDES | May 2023 | May 2025 | Allow | 24 | 1 | 0 | No | No |
| 18142512 | MULTIPLEXED METHOD FOR THE IDENTIFICATION AND QUANTITATION OF MINOR ALLELES AND POLYMORPHISMS | May 2023 | July 2025 | Allow | 26 | 2 | 0 | No | No |
| 18303536 | COMPOSITIONS AND METHODS FOR ISOLATION OF CELL-FREE DNA | April 2023 | October 2024 | Allow | 18 | 1 | 0 | No | No |
| 18131675 | DNA SEQUENCING REACTION ADDITIVE | April 2023 | April 2025 | Abandon | 24 | 1 | 0 | No | No |
| 18129747 | CONFORMATIONAL PROBES AND METHODS FOR SEQUENCING NUCLEIC ACIDS | March 2023 | January 2025 | Allow | 22 | 1 | 0 | No | No |
| 18125041 | LOADING NUCLEIC ACIDS ONTO SUBSTRATES | March 2023 | November 2024 | Allow | 20 | 1 | 0 | No | No |
| 18184928 | METHODS AND COMPOSITIONS FOR SEQUENCING DOUBLE STRANDED NUCLEIC ACIDS | March 2023 | June 2025 | Allow | 27 | 2 | 0 | No | No |
| 18111791 | Colorimetric Detection of Nucleic Acid Amplification | February 2023 | March 2025 | Allow | 25 | 2 | 0 | No | No |
| 18106566 | PURIFICATION OF NUCLEIC ACIDS USING TITANIUM OXIDES | February 2023 | October 2024 | Allow | 20 | 1 | 0 | No | No |
| 18164531 | DEVICE FOR EXTRACTING A NUCLEIC ACID FROM A SAMPLE LIQUID | February 2023 | February 2025 | Allow | 25 | 1 | 0 | No | No |
| 18053603 | ERROR CORRECTION IN AMPLIFICATION OF SAMPLES | November 2022 | March 2025 | Allow | 28 | 3 | 0 | No | No |
| 18050382 | SEQUENCE TAG DIRECTED SUBASSEMBLY OF SHORT SEQUENCING READS INTO LONG SEQUENCING READS | October 2022 | July 2024 | Allow | 21 | 1 | 0 | No | No |
| 18046058 | PRIMER EXTENSION TARGET ENRIGHMENT AND IMPROVEMENTS THERETO INCLUDING SIMULTANEOUS ENRICHMENT OF DNA AND RNA | October 2022 | January 2025 | Allow | 27 | 1 | 1 | No | No |
| 17934407 | METHODS OF SEQUENCING CIRCULAR TEMPLATE POLYNUCLEOTIDES | September 2022 | September 2024 | Allow | 24 | 3 | 0 | No | No |
| 17820011 | METHOD OF NUCLEIC ACID ENRICHMENT USING SITE-SPECIFIC NUCLEASES FOLLOWED BY CAPTURE | August 2022 | August 2024 | Allow | 24 | 1 | 1 | No | No |
| 17819397 | SYSTEMS AND METHODS FOR PROCESSING-NUCLEIC ACID MOLECULES FROM A SINGLE CELL USING SEQUENTIAL CO-PARTITIONING AND COMPOSITE BARCODES | August 2022 | July 2024 | Allow | 23 | 1 | 0 | No | No |
| 17886769 | TCR/BCR Profiling Using Enrichment with Pools of Capture Probes | August 2022 | May 2024 | Allow | 22 | 1 | 0 | No | No |
| 17816662 | Sequencing Output Determination and Analysis with Target-Associated Molecules in Quantification Associated with Biological Targets | August 2022 | August 2024 | Allow | 25 | 2 | 0 | No | No |
| 17828686 | DNA CONSTRUCT FOR SEQUENCING AND METHOD FOR PREPARING THE SAME | May 2022 | March 2025 | Allow | 34 | 1 | 0 | Yes | No |
| 17749050 | SYSTEMS AND METHODS FOR DIFFERENTIALLY TAGGING NUCLEIC ACID MOLECULES | May 2022 | July 2024 | Allow | 26 | 1 | 0 | No | No |
| 17502526 | METHODS AND COMPOSITIONS FOR CAPPING NUCLEIC ACIDS | October 2021 | September 2024 | Allow | 35 | 1 | 0 | Yes | No |
| 17497090 | Methods for Categorizing and Treating Subjects Having Cystic Fibrosis (CF) and at Risk for Severe Pulmonary Exacerbation | October 2021 | July 2024 | Allow | 33 | 3 | 0 | No | No |
| 17602643 | COMPOSITION FOR DIAGNOSIS OR PROGNOSIS PREDICTION OF GLIOMA, AND METHOD FOR PROVIDING INFORMATION RELATED THERETO | October 2021 | March 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17492318 | Systems and Methods for Rapid Nucleic Acid Extraction, Purification and Analysis from Semen | October 2021 | April 2025 | Allow | 42 | 1 | 1 | Yes | No |
| 17600526 | IMMOBILIZATION IN FLOW CELLS | September 2021 | April 2025 | Allow | 42 | 0 | 1 | No | No |
| 17448736 | DETERMINING THE SEQUENCE OF A DOUBLE-STRANDED TARGET NUCLEIC ACID BY EMPLOYING A TERMINAL TRANSFERASE, FORMING A LINEAR JOINT MOLECULE, AND SEQUENCING IN ONE DIRECTION | September 2021 | November 2024 | Allow | 38 | 1 | 0 | No | No |
| 17483274 | AFFINITY-OLIGONUCLEOTIDE CONJUGATES AND USES THEREOF | September 2021 | October 2024 | Abandon | 37 | 1 | 0 | No | No |
| 17447794 | METHODS FOR PREPARING A SAMPLE FOR NUCLEIC ACID AMPLIFICATION USING TAGMENTATION | September 2021 | August 2024 | Allow | 35 | 1 | 1 | Yes | No |
| 17399339 | METHOD FOR QUANTIFICATION OF PD-L1 EXPRESSION | August 2021 | January 2025 | Allow | 42 | 3 | 0 | Yes | No |
| 17392531 | ISOTHERMAL METHODS FOR AMPLIFYING NUCLEIC ACID SAMPLES | August 2021 | May 2025 | Allow | 46 | 1 | 0 | No | No |
| 17392865 | SINGLE CELL BAR-CODING FOR ANTIBODY DISCOVERY | August 2021 | May 2024 | Allow | 34 | 1 | 1 | No | No |
| 17384635 | XENONUCLEIC ACID-MEDIATED MULTIPLEX QPCR CLAMPING TECHNOLOGY FOR LUNG CANCER MUTATION DETECTION | July 2021 | February 2025 | Abandon | 43 | 2 | 0 | Yes | No |
| 17345011 | METHOD COMBINING SINGLE CELL GENE EXPRESSION MAPPING AND TARGETED RNA OR c-DNA SEQUENCING USING PADLOCK OLIGONUCLEOTIDES COMPRISING A BARCODE REGION | June 2021 | August 2024 | Allow | 38 | 2 | 0 | No | No |
| 17293578 | SYSTEMS AND METHODS FOR CHARACTERIZING AND TREATING BREAST CANCER | May 2021 | July 2024 | Allow | 38 | 1 | 1 | Yes | No |
| 17281269 | FULL-LENGTH RNA SEQUENCING | March 2021 | December 2024 | Allow | 45 | 1 | 0 | No | No |
| 17217797 | Analytical Toilet for Detecting Viruses in Urine | March 2021 | December 2024 | Abandon | 45 | 0 | 1 | No | No |
| 17218121 | METHODS FOR NUCLEIC ACID SEQUENCING | March 2021 | October 2024 | Abandon | 43 | 7 | 1 | Yes | No |
| 17206701 | METHODS FOR HAPLOTYPING WITH SHORT READ SEQUENCE TECHNOLOGY | March 2021 | January 2025 | Abandon | 46 | 1 | 0 | No | No |
| 17181103 | METHODS AND KITS FOR EXTRACTION OF DNA | February 2021 | July 2024 | Allow | 40 | 2 | 1 | No | No |
| 17257370 | Methods for Detecting and Treating a Tumorigenic Phenotype of the Liver | December 2020 | May 2025 | Allow | 53 | 2 | 1 | No | Yes |
| 16328141 | PROCESS FOR THE ENZYMATIC SYNTHESIS AND AMPLIFICATION OF NUCLEIC ACIDS | February 2019 | November 2019 | Allow | 9 | 1 | 0 | No | No |
| 16007795 | COLORECTAL CANCER ASSOCIATED CIRCULATING NUCLEIC ACID BIOMARKERS | June 2018 | March 2025 | Allow | 60 | 3 | 1 | No | Yes |
| 15577093 | KIT FOR PREDICTING TREATMENT WITH GLUCOCORTICOIDS AND METHOD COMPRISING THE SAME | November 2017 | February 2020 | Allow | 27 | 1 | 0 | No | No |
| 15730608 | METHODS OF ASSAYING NUCLEIC ACIDS OF LOW QUANTITIES USING A BUFFER NUCLEIC ACID | October 2017 | February 2020 | Allow | 28 | 1 | 1 | Yes | No |
| 15276912 | NOVEL PCR PRIMERS AND METHODS THEREOF FOR THE IDENTIFICATION OF BACILLUS COAGULANS | September 2016 | January 2019 | Allow | 28 | 2 | 0 | No | No |
| 15032983 | Method for Analyzing Body Fluid Samples | April 2016 | October 2018 | Allow | 30 | 1 | 0 | No | No |
| 14909840 | NUCLEIC ACID AMPLIFICATION DEVICE, NUCLEIC ACID AMPLIFICATION APPARATUS, AND NUCLEIC ACID AMPLIFICATION METHOD FOR TRANSPORTING REACTION SOLUTION INCLUDING TARGET NUCLEIC ACID VIA CAPILLARY FORCE TO AMPLIFY TARGET NUCLEIC ACID | February 2016 | September 2018 | Allow | 32 | 1 | 0 | No | No |
| 14903416 | DNA AMPLIFICATION VIA SCISSOR-LIKE STRUCTURES (DASL) | January 2016 | July 2018 | Allow | 30 | 1 | 0 | No | No |
| 14834710 | METHODS, COMPOSITIONS AND KITS FOR ENRICHING FOR A MINOR TEMPLATE AMPLIFICATION PRODUCT IN A MIXED TEMPLATE AMPLIFICATION REACTION | August 2015 | March 2016 | Allow | 7 | 2 | 0 | No | No |
| 14762454 | QUANTIFICATION METHOD FOR EXPRESSION LEVEL OF WT1 mRNA | July 2015 | December 2018 | Allow | 41 | 2 | 0 | Yes | No |
| 14743901 | METHOD OF EXTENDING DNA WITH TELOMERASE AND METHOD OF MEASURING TELOMERASE ACTIVITY | June 2015 | January 2019 | Allow | 43 | 4 | 0 | Yes | No |
| 14679647 | SOYBEAN EVENT 127 AND METHODS RELATED THERETO | April 2015 | January 2018 | Allow | 34 | 1 | 1 | No | No |
| 14613849 | METHOD FOR GENOME SEQUENCING USING A SEQUENCE-BASED PHYSICAL MAP | February 2015 | November 2015 | Allow | 9 | 1 | 0 | No | No |
| 14610915 | Recombinase Polymerase Amplification | January 2015 | December 2015 | Allow | 10 | 1 | 0 | No | No |
| 14404964 | ASSEMBLY AND METHOD FOR ANALYZING NUCLEIC ACID SEQUENCES BY WAY OF SO-CALLED SEQUENCING-BY-SYNTHESIS | December 2014 | May 2017 | Allow | 30 | 1 | 0 | Yes | No |
| 14522505 | NUCLEIC ACID-FREE THERMOSTABLE ENZYMES AND METHODS OF PRODUCTION THEREOF | October 2014 | July 2016 | Allow | 20 | 2 | 0 | Yes | No |
| 14382142 | METHOD OF IDENTIFYING VDJ RECOMBINATION PRODUCTS | August 2014 | August 2017 | Allow | 36 | 1 | 1 | No | No |
| 14304543 | KIT COMPRISING PRIMERS FOR AMPLIFYING ALK KINASE DOMAIN NUCLEIC ACIDS | June 2014 | June 2015 | Allow | 12 | 2 | 1 | Yes | No |
| 14343511 | A PRIMER SET FOR ISOTHERMAL AMPLICATION OF A TARGET NUCLEIC ACID SEQUENCE. | June 2014 | December 2016 | Allow | 33 | 1 | 0 | No | No |
| 14274168 | METHODS TO REDUCE REPEATS OF IDENTICAL NUCLEOTIDES IN COPIES OF A TARGET DNA MOLECULE INCLUDING SUCH REPEATS | May 2014 | March 2017 | Allow | 34 | 1 | 1 | No | No |
| 14219931 | METHOD FOR THE IDENTIFICATION OF THE CLONAL SOURCE OF A RESTRICTION FRAGMENT | March 2014 | November 2014 | Allow | 8 | 2 | 0 | No | No |
| 14172793 | A Method for Detection of High Risk Human Papillomavirus | February 2014 | August 2016 | Allow | 30 | 2 | 0 | No | No |
| 14062228 | NUCLEIC ACID EXTRACTION DEVICE, AND NUCLEIC ACID EXTRACTION METHOD, NUCLEIC ACID EXTRACTION KIT, AND NUCLEIC ACID EXTRACTION APPARATUS, EACH USING THE SAME | October 2013 | January 2016 | Allow | 27 | 1 | 1 | Yes | No |
| 13948928 | NUCLEIC ACID-FREE THERMOSTABLE ENZYMES AND METHODS OF PRODUCTION THEREOF | July 2013 | July 2014 | Allow | 12 | 2 | 0 | Yes | No |
| 13922146 | COMPOSITIONS FOR AMPLIFICATION OF RNA SEQUENCES USING COMPOSITE PRIMERS | June 2013 | July 2015 | Allow | 25 | 2 | 0 | No | No |
| 13911268 | COMPOSITIONS FOR RECOMBINASE POLYMERASE AMPLIFICATION | June 2013 | February 2016 | Allow | 32 | 2 | 0 | No | No |
| 13874697 | DETECTION OF NUCLEIC ACID SEQUENCE DIFFERENCES USING COUPLED LIGASE DETECTION AND POLYMERASE CHAIN REACTIONS | May 2013 | March 2014 | Allow | 11 | 1 | 0 | No | No |
| 13783601 | METHOD FOR THE IDENTIFICATION OF THE CLONAL SOURCE OF A RESTRICTION FRAGMENT | March 2013 | November 2013 | Allow | 8 | 1 | 0 | No | No |
| 13779459 | METHODS FOR PREPARING AMPLIFIABLE DNA MOLECULES | February 2013 | March 2014 | Allow | 12 | 1 | 0 | No | No |
| 13648415 | PRESERVATION OF CELL-FREE RNA IN BLOOD SAMPLES | October 2012 | July 2013 | Allow | 9 | 1 | 0 | No | No |
| 13543432 | DETECTION OF NUCLEIC ACID SEQUENCE DIFFERENCES USING COUPLED POLYMERASE CHAIN REACTIONS | July 2012 | June 2013 | Allow | 11 | 1 | 0 | No | No |
| 13543365 | DETECTION OF NUCLEIC ACID SEQUENCE DIFFERENCES USING COUPLED LIGASE DETECTION AND POLYMERASE CHAIN REACTIONS | July 2012 | February 2013 | Allow | 8 | 1 | 0 | No | No |
| 13523252 | DETECTION OF NUCLEIC ACID SEQUENCE DIFFERENCES USING COUPLED LIGASE DETECTION AND POLYMERASE CHAIN REACTIONS | June 2012 | February 2013 | Allow | 8 | 1 | 0 | No | No |
| 13505694 | GENOTYPING OF N LOCI IN A TARGET NUCLEIC ACID MOLECULE | May 2012 | January 2016 | Allow | 44 | 1 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HORLICK, KENNETH R.
With a 100.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 34.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner HORLICK, KENNETH R works in Art Unit 1681 and has examined 325 patent applications in our dataset. With an allowance rate of 96.6%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 30 months.
Examiner HORLICK, KENNETH R's allowance rate of 96.6% places them in the 90% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by HORLICK, KENNETH R receive 1.78 office actions before reaching final disposition. This places the examiner in the 53% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by HORLICK, KENNETH R is 30 months. This places the examiner in the 39% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +0.1% benefit to allowance rate for applications examined by HORLICK, KENNETH R. This interview benefit is in the 12% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 33.6% of applications are subsequently allowed. This success rate is in the 67% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 64.8% of cases where such amendments are filed. This entry rate is in the 86% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 93% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 92.6% of appeals filed. This is in the 82% percentile among all examiners. Of these withdrawals, 84.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 58.2% are granted (fully or in part). This grant rate is in the 74% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 24.0% of allowed cases (in the 99% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.6% of allowed cases (in the 51% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.